[go: up one dir, main page]

HUP9900733A3 - Use of imidazo[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with difunction of the neural circuits of the basal ganglia - Google Patents

Use of imidazo[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with difunction of the neural circuits of the basal ganglia

Info

Publication number
HUP9900733A3
HUP9900733A3 HU9900733A HUP9900733A HUP9900733A3 HU P9900733 A3 HUP9900733 A3 HU P9900733A3 HU 9900733 A HU9900733 A HU 9900733A HU P9900733 A HUP9900733 A HU P9900733A HU P9900733 A3 HUP9900733 A3 HU P9900733A3
Authority
HU
Hungary
Prior art keywords
difunction
imidazo
pyridine
therapeutic treatment
basal ganglia
Prior art date
Application number
HU9900733A
Other languages
English (en)
Original Assignee
Clarendon Trading And Investim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarendon Trading And Investim filed Critical Clarendon Trading And Investim
Publication of HUP9900733A2 publication Critical patent/HUP9900733A2/hu
Publication of HUP9900733A3 publication Critical patent/HUP9900733A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU9900733A 1995-04-07 1996-04-02 Use of imidazo[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with difunction of the neural circuits of the basal ganglia HUP9900733A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000223A IT1276522B1 (it) 1995-04-07 1995-04-07 Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei

Publications (2)

Publication Number Publication Date
HUP9900733A2 HUP9900733A2 (hu) 1999-07-28
HUP9900733A3 true HUP9900733A3 (en) 2003-05-28

Family

ID=11403250

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900733A HUP9900733A3 (en) 1995-04-07 1996-04-02 Use of imidazo[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with difunction of the neural circuits of the basal ganglia

Country Status (25)

Country Link
US (1) US5891891A (hu)
EP (1) EP0819002B1 (hu)
JP (1) JP4049390B2 (hu)
KR (1) KR100425628B1 (hu)
CN (1) CN1198612C (hu)
AR (1) AR003414A1 (hu)
AT (1) ATE222763T1 (hu)
AU (1) AU707759B2 (hu)
CA (1) CA2217590C (hu)
CZ (1) CZ292020B6 (hu)
DE (1) DE69623271T2 (hu)
DK (1) DK0819002T3 (hu)
EA (1) EA000396B1 (hu)
ES (1) ES2182967T3 (hu)
HU (1) HUP9900733A3 (hu)
IL (1) IL117824A (hu)
IT (1) IT1276522B1 (hu)
MX (1) MX9707712A (hu)
NO (1) NO315408B1 (hu)
NZ (1) NZ304107A (hu)
PL (1) PL322647A1 (hu)
PT (1) PT819002E (hu)
TW (1) TW450816B (hu)
WO (1) WO1996031210A1 (hu)
ZA (1) ZA962711B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6333345B1 (en) 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
EP1272181A2 (en) * 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent
IL152411A0 (en) * 2000-04-24 2003-05-29 Teva Pharma Zolpidem hemitartrate
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
GB0311457D0 (en) * 2003-05-19 2003-06-25 Sciencom Ltd New therapeutic use
AU2004237943A1 (en) 2003-05-19 2004-11-25 Sciencom Ltd Further therapeutic use of zolpidem
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050267176A1 (en) 2004-02-18 2005-12-01 Sepracor Inc. Dopamine-agonist combination therapy for improving sleep quality
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2007065559A1 (en) * 2005-11-18 2007-06-14 Synthon B.V. Zolpidem tablets
GB2443928A (en) * 2006-11-08 2008-05-21 Regen Therapeutics Plc Transdermal pharmaceutical composition comprising Zolpidem
GB0809936D0 (en) * 2008-05-30 2008-07-09 Regen Therapeutics Plc Therapeutic use of zolpidem
EP3468545A4 (en) 2016-06-08 2020-07-22 President and Fellows of Harvard College METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME AND FRAGILE X SYNDROME
AU2019272778B2 (en) 2018-05-22 2024-10-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
WO2020198275A1 (en) 2019-03-25 2020-10-01 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5032595A (en) * 1989-11-24 1991-07-16 Fidia-Georgetown Institute For The Neurosciences Method of stimulating steroidogenesis with alpidem
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
CZ316797A3 (cs) 1998-05-13
EP0819002B1 (en) 2002-08-28
EA199700308A1 (ru) 1998-04-30
DK0819002T3 (da) 2003-01-06
ES2182967T3 (es) 2003-03-16
JP4049390B2 (ja) 2008-02-20
JPH11503149A (ja) 1999-03-23
HUP9900733A2 (hu) 1999-07-28
CA2217590A1 (en) 1996-10-10
KR19980703707A (ko) 1998-12-05
IL117824A (en) 2000-08-31
CZ292020B6 (cs) 2003-07-16
CA2217590C (en) 2008-08-12
CN1198612C (zh) 2005-04-27
ITRM950223A1 (it) 1996-10-07
IT1276522B1 (it) 1997-10-31
MX9707712A (es) 1998-03-31
AU707759B2 (en) 1999-07-22
EP0819002A1 (en) 1998-01-21
CN1183719A (zh) 1998-06-03
AU5120096A (en) 1996-10-23
KR100425628B1 (ko) 2004-06-23
DE69623271T2 (de) 2003-07-24
DE69623271D1 (de) 2002-10-02
NO315408B1 (no) 2003-09-01
AR003414A1 (es) 1998-08-05
ATE222763T1 (de) 2002-09-15
ZA962711B (en) 1996-07-30
IL117824A0 (en) 1996-08-04
NO974603D0 (no) 1997-10-06
TW450816B (en) 2001-08-21
PL322647A1 (en) 1998-02-16
NZ304107A (en) 2000-12-22
WO1996031210A1 (en) 1996-10-10
ITRM950223A0 (it) 1995-04-07
US5891891A (en) 1999-04-06
NO974603L (no) 1997-11-24
PT819002E (pt) 2003-01-31
EA000396B1 (ru) 1999-06-24

Similar Documents

Publication Publication Date Title
HUP9900733A3 (en) Use of imidazo[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with difunction of the neural circuits of the basal ganglia
ZA897699B (en) Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
ZA928832B (en) Local delivery of dipyridamole for the treatment of proliferative diseases
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
HU9401317D0 (en) Antiviral 2-ethyl - 1h imidazo (4,5-c) quinolin-4-amines
NO305886B1 (no) Anvendelse av et organisk nitritt for fremstilling av medikamenter for kontinuerlig, vasodilatorisk terapi
FI92401B (fi) Menetelmä valmistaa farmakologisesti arvokasta pyrrolo/3,2,1-jk//1,4/bentsodiatsepiinijohdannaista
FI922848L (fi) Menetelmä valmistaa terapeuttisesti aktiivisia tetrahydropyrrolo[1,2-a]pyratsiini-4-spiro-3'-pyrrolidiinijohdannaisia
ZA952860B (en) Substituted tricyclic imidazo[1,2-a]pyridines useful in the prevention and treatment of gastrointestinal inflammatory disease
IL104706A0 (en) 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-ones and process for the preparation thereof
FI900084A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsol-2-yyli- ja imidatso/4,5-b/pyridin-2-yyli-amino- ja -metyyli-1-piperidinyylietyylijohdannaisten valmistamiseksi
HUP0201280A3 (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
HU9500171D0 (en) Tetracyclic compounds process and intermediated for their preparation and their use as antitumour agents
AU4859596A (en) Imidazo{1,2-a}pyridines for the treatment of cns and cardiac diseases
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
NZ229346A (en) Oxadiazolyl-substituted imidazo(1,5-a)quinoxaline derivatives and pharmaceutical compositions
NZ224032A (en) Imidazo(1,2-a)pyridine derivatives and pharmaceutical compositions
EP0554098A3 (en) Process for the preparation of imidazo 4,5-b pyridine derivatives
HUP9901258A3 (en) Imidazo[2,1-b]thiazole and thiazolo[3,2-a]pyrimidine derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
FI890478A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4-okso-4H-pyrido/1,2-a/pyrimidiini-3-karboksamidijohdannaisten valmistamiseksi
EP0436831A3 (en) Imidazo(1,2-a)pyridinylalkyl compounds for treatment of neurotoxic injury
FI884017A7 (fi) Pyrrolo /1,2-a/ imidatsoli- ja imidatso /1,2-a/-pyridiinijohdannaisia ja niiden käyttö 5-lipoksigenaasijohtoradan inhibiittoreina.
EP0458640A3 (en) Use of ergoline derivatives for the treatment of diseases associated with bone demineralization
FR2699920B1 (fr) Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
GB2205565B (en) Imidazo-[1,2-a]-pyrimidin-2-oyl and imidazo-[1,2-a]quinazolin-2-oyl cyclopropane derivatives

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished